Suchergebnisse - "Bourlière, Marc"

PubPharm (408)

1

Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France : A nationwide claims data analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2024

von Lam, L. | Carrieri, P. | Hejblum, G. | +3

2

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B : REEF-2

enthalten in: Journal of hepatology | 2024

von Agarwal, K. | Buti, M. | van Bömmel, F. | +14

3

Management of chronic HBV-HDV patients chronic HBV-HDV infection : A review on new management options

enthalten in: United European gastroenterology journal | 2024

von Buti, M. | Gonzalez, A. | Riveiro-Barciela, M. | +1

4

Hepatitis C virus cure from direct-acting antivirals and mortality : Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort)

enthalten in: Drug and alcohol review | 2024

von Barré, T. | Bourlière, M. | Parlati, L. | +11

5

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis

enthalten in: Hepatology (Baltimore, Md.) | 2024

von Nahon, P. | Layese, R. | Ganne-Carrié, N. | +69

6

Hepatitis C virus cure from direct‐acting antivirals and mortality : Are people with and without a history of injection drug use in the same boat? ( ANRS CO22 Hepather cohort)

enthalten in: Drug and Alcohol Review | 2024

von Barré, T. | Bourlière, M. | Parlati, L. | +10

7

Management of chronic HBV‐HDV patients chronic HBV‐HDV infection : A review on new management options

enthalten in: United European Gastroenterology Journal | 2024

von Buti, M. | Gonzalez, A. | Riveiro‐Barciela, M. | +1

8

Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France : A nationwide claims data analysis

enthalten in: Liver International | 2024

von Lam, L. | Carrieri, P. | Hejblum, G. | +3

9

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) : a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Llovet, J. | Kudo, M. | Merle, P. | +123

ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547896

10

Impaired health-related quality of life in the HCV cure era : who is concerned? (ANRS CO22 HEPATHER French cohort)

enthalten in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation | 2023

von Carrieri, P. | Bourlière, M. | Di Beo, V. | +112

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[41]